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Background: The 3-weekly combination of trastuzumab and paclitaxel has been approved for the treatment of
advanced breast cancer based on a large pivotal study. However, mono and combination chemotherapy trials
suggest that weekly paclitaxel has a better therapeutic index, especially in the palliative setting. The present trial
examined the efficacy and safety of weekly paclitaxel over a limited duration combined with continued trastuzumab
in HER2+ patients.
Methods: Patients with histologically confirmed metastatic breast cancer overexpressing HER2 were eligible if
pretreated with anthracycline in either the adjuvant or palliative setting. Treatment consisted of weekly trastuzumab
(2 mg/kg/week for up to one year after a loading dose of 4 mg/kg in week 1) and paclitaxel (90 mg/m²,
administered in weeks 1–6 and 8–13).
Results: Twenty-seven German centers enrolled 121 patients. The median number of metastatic sites was two
(range 1–5); 38% of patients had received chemotherapy for advanced disease. After a median 42 weeks of
trastuzumab treatment, limited by disease progression in roughly half the patients, a best objective response rate
(complete response + partial response) of 76% was achieved, including complete remissions in 29%. 74% of patients
lived without tumor progression at six months. Median progression-free and overall survival were 9.4 (95%
confidence interval [CI]: 8.1–11.3) and 22 months (95% CI: 17–46). After alopecia, Common Toxicity Criteria grade ≥2
toxicity was predominantly hematological (leukopenia [31%] and anemia [41%]); however, thrombocytopenia
occurred in only 5%. Neurotoxicity was remarkably low. Two cardiac events (grades 2 and 3) were presumed
treatment-related.
Conclusions: Weekly paclitaxel plus trastuzumab allows an increased dose density and offers an attractive and
effective alternative to the conventional schedule. Limiting the duration of cytotoxic therapy to 3 months seems to
be an option to reduce neurotoxicity without impairing long-term outcome.Background
Recent advances in understanding cancer biology have
spurred the development of a plethora of targeted agents
that have revolutionized the treatment of a number of
malignancies. Their mechanism of action often depends
on specific molecular features allowing for individualized
strategies, in contrast to the non-selective approaches of
the conventional chemotherapy era. The best known and
most successful example was the discovery that 20 to* Correspondence: dr.matthias.john@web.de
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reproduction in any medium, provided the orig25% of advanced breast cancer patients overexpress
human epidermal growth factor receptor type 2 (HER2)
[1]. This led to the development of trastuzumab (Her-
ceptin®), a humanized monoclonal antibody against this
epitope [2] that shows considerable antitumor efficacy as
a single agent even in heavily pretreated patients with
advanced disease [3,4].
Nevertheless, based on preclinical evidence of synergy
[5], the major breakthrough of this targeted approach
was to combine the antibody with cytostatic drugs, in
both early and advanced disease [2]. The pivotal rando-
mized phase III study on combination trastuzumab in. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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backbones: either doxorubicin/cyclophosphamide or sin-
gle-agent paclitaxel, both given 3-weekly [6]. While added
trastuzumab increased response and survival rates in each
of these strata, combination with anthracyclines unexpect-
edly increased cardiotoxicity [7] (although less markedly
with epirubicin [8]), impeding its widespread use and
favoring taxane-oriented strategies.
During the same period evidence emerged that weekly
(rather than 3-weekly) paclitaxel achieved high antitumor
activity thanks to a considerably increased dose intensity
and/or densitiy, yet with no apparent increase in overall
toxicity [9,10]. We therefore assessed the efficacy and
safety of weekly paclitaxel over a recommended duration
of just 3 months while continuing trastuzumab in HER2-
positive patients with advanced breast cancer previously
treated with anthracyclines.
Methods
The non-commercial multicenter study was conducted
according to the principles of the Declaration of Helsinki
(1996 version). Approval was gained from the institu-
tional review boards of all 27 participating centers and
each patient gave prior written informed consent.
Eligibility criteria
Patients with histologically confirmed metastatic breast
cancer overexpressing HER2 were eligible if pretreated with
anthracycline in either the adjuvant or palliative setting.
HER2 positivity was defined as 2+ or 3+ overexpression
using the DAKO HercepTest™, confirmed by fluorescence
in-situ hybridization (FISH) if 2+. Non-inclusion criteria
were >1 chemotherapy for advanced disease, taxane or tras-
tuzumab pretreatment, brain metastases, Eastern Coopera-
tive Oncology Group (ECOG) performance status >1 at
screening, pregnancy or lactation, childbearing potential
without reliable contraception, clinically significant cardiac
disease, neutrophils <1500/μl, platelets <75,000/μl, and
total bilirubin and creatinine >1.5 × the upper limit of
normal.
Study treatment
Patients received an intravenous (iv) loading dose of tras-
tuzumab 4 mg/kg body weight on day 0 over an infusion
duration of 90 min, followed by an infusion of paclitaxel
90 mg/m2 over 1 hour on day 1. From day 8, the same
paclitaxel regimen and infusions of trastuzumab 2 mg/kg
body weight were administered on the same day every
week. The cytotoxic drug was given over two 6-week
blocks separated by a 14-day break, with optional pro-
longation at the physician’s discretion; the antibody was
continued weekly until disease progression. Premedica-
tion (all iv) was dexamethasone 10 mg, clemastine 2 mg,
and ranitidine 50 mg.The paclitaxel dose was reduced to 75 mg/m2 in the
event of grade 3/4 hematotoxicity, and stopped com-
pletely in the event of grade 3 neurotoxicity or severe
hypersensitivity reactions. Termination of trastuzumab
was considered in the event of persisting asymptomatic
deterioration of left ventricular ejection fraction or
symptomatic heart disease.
Evaluation of safety and efficacy
Baseline documentation included demographics, medical
and treatment history, cardiac function, and HER/2neu
status. Vital signs, ECOG performance status, and
complete blood counts were recorded at baseline and
each weekly visit, serum chemistry at baseline and 4-
weekly. Tumor assessment comprised physical examin-
ation and radiology at baseline, after each paclitaxel
treatment block, and 8-weekly thereafter. Tumor re-
sponse and progression were evaluated using World
Health Organization (WHO) criteria. Time to progres-
sion was defined as the period between study enrolment
and progression or death, whichever occurred first.
Cotreatments and adverse events (graded using National
Cancer Institute Common Toxicity Criteria NCI-CTC)
were recorded continuously throughout the study. Elec-
trocardiography and echocardiography were repeated 12-
weekly.
Statistical aspects
The primary objective of this phase II study was the
progression-free survival (PFS) rate at 6 months. 115
patients were required to discriminate a promising 50%
PFS rate from a futile finding of 35% with both type I and
II errors of 5% [11]. All other parameters were analyzed
descriptively in terms of standard distribution parameters
such as rates, means with standard deviations, quartiles,
and ranges. Event-related data (PFS, overall survival) were
estimated using the product limit method of Kaplan and
Meier [12]. Two-sided logrank tests were used to compare
prognostic subgroups [13].
Results
Twenty-seven German centers in the FAKT Study Group
enrolled 121 patients from February 2001 to July 2004.
Ten proved ineligible: eight had not received anthracycline
pretreatment, one had been pretreated with paclitaxel, and
one was found to have been enrolled retrospectively. A
further three patients were removed from the analysis due
to missing documentation or serious protocol violation
(radiotherapy to the only site of disease), leaving 108 cases
for the baseline and safety analyses. Between one and three
patients had insufficient data for the analysis of the re-
spective efficacy parameters. Disease was aggressive in
most patients, with a median of two organ sites involved
and visceral lesions present in about 80% (Table 1). Most
Table 1 Patient and tumor characteristics (n = 108)
n/estimation %
Age (years)
Mean ± standard deviation 58.4 ± 10.2
Median (range) 59 (29–78)





2+/FISH + 8 7
3+ 97 90
FISH +/no immunohistochemistry or other 3 3




Metastatic sites at onset of study treatment (n)
Mean ± standard deviation 1.8 ± 0.9
Median, range 2 (1–5)
Organ site involvement
Local/skin 14 13








Neoadjuvant chemotherapy 11 10
Adjuvant chemotherapy 74 69
Adjuvant endocrine therapy 45 42
Palliative chemotherapy 40 37
Palliative endocrine therapy 34 31
Abbreviations
ECOG: Eastern Cooperative Oncology Group.
FISH: fluorescence in-situ hybridization.
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ting, with the result that a high proportion of patients
(63%) received their first-line palliative chemotherapy in
this study. Thirteen patients (12%) had a history of heart
disease.Efficacy
The recommended duration of paclitaxel treatment was
followed in most patients. Cycle numbers were 12 (me-
dian) and 12.6 (mean); 16% of patients received fewer
than 12 cycles due to early progression or toxicity; 73%
and 12% received 12 and >12 cycles. The mediannumber of trastuzumab doses was 42; antibody therapy
lasted ≥1 year in almost half the patients (48%). Treat-
ment withdrawal due to severe toxicity (6%) or patient
preference (12%) was uncommon. Tumor response was
assessable in 105 patients. The overall objective remis-
sion rate was 76% (95% confidence interval [CI]: 67–
84%), with 30 (29%) complete responses (CR) and 50
(48%) partial responses (PR), equivalent to a response
rate of 74% based on an intention-to-treat population of
all eligible cases. Only 7% of patients had direct progres-
sion with no period of at least stable disease while on
study treatment. Based on a follow-up period of up to
more than 4 years and 85 observed events, median PFS
was 9.4 months in the total population (Figure 1), with a
6-month PFS rate of 74% (95% CI: 65–83%), representing
a highly promising result with respect to the predefined
primary endpoint. Almost half the patients were alive
more than 2 years after entering the study (Figure 2).Prognostic factors
The impact of several prognostic characteristics on the
primary endpoint was analyzed. PFS was significantly
longer in the absence of hepatic involvement (P = 0.022),
especially in the subgroup with a generally better prog-
nosis (Figure 3), as in those with only one site of metas-
tasis (Figure 4, P = 0.0047). In contrast, neither an ECOG
score ≥1 nor palliative pretreatment with chemotherapy
were significant predictors of poorer outcome. Hepatic
and visceral involvement had no significant impact on
tumor remission, but response was significantly more
frequent in patients with only one site of disease (91%
CR/PR, P< 0.0001). CR was most frequently observed in
patients with intact performance status and no liver
metastases.Safety
Leukopenia occurred in most cases, but reached NCI-
CTC grade 3/4 in only 14% (Table 2). Mild to moderate
anemia was very common, and thrombocytopenia com-
paratively rare. Peripheral sensory neuropathy and pain
were the most frequent severe non-hematological events,
typically accompanied by arthralgia and myalgia. There
was no instance of grade ≥2 gastrointestinal toxicity, ex-
cept one case of life-threatening diarrhea. Clinical chem-
istry showed no grade 3/4 nephrotoxicity; severe liver
enzyme elevation occurred in 5%. There were five cases
of hypersensitivity, three out of these of severe grade..
Lung function deteriorated severely in five patients, in-
cluding one case of grade 3 dyspnea, described as cardio-
toxicity, but observed in a patient with pleural effusion.
Cardiac symptoms (grade 2) were reported in only one
patient.



















n = 106, 85 events, median = 9.4 months
Figure 1 Time to progression in the total population.
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As the first therapeutic antibody approved for solid
tumors, trastuzumab was introduced into the first-line
treatment of advanced breast cancer based on a pivotal
randomized study assessing its efficacy in combination
with cytostatic drugs: combination with 3-weekly pacli-
taxel clearly outperformed chemotherapy alone, achieving
an overall response rate of 41%, a median time to progres-
sion of 6.9 months, and overall survival of 22 months [6].
This was confirmed by corresponding results of 36%, 7.1















n = 107, 44 events, median = 21.6 months
Figure 2 Overall survival in the total population.comparing this combination to a three-drug regimen
comprising paclitaxel, trastuzumab, and carboplatin [14].
Smaller phase II studies on the combination of the HER2
antibody with docetaxel have reported response rates of 50
to 70% [15-17].
Weekly paclitaxel proved a dose-dense alternative to
the 3-weekly regimen, achieving at least similar activity
in breast and lung cancer, and showing some advantages
in terms of feasibility and decreased toxicity. The results
of our trial, notably a median PFS of 9.4 months and an
overall survival of 22 months, compare favorably to theonths
30 35 40 45 50 55 60



















Logrank test: p = 0.022
Liver not involved: n = 58, 43 events, median = 9.9 mo.
Liver  involved: n = 48, 42 events, median = 8.3 months
Figure 3 Time to progression by hepatic involvement.
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37% of patients with previous palliative chemotherapy.
The intention-to-treat response rate of 74% is consider-
ably higher, but this may be due to the more rigorous
focus on remission confirmation in pivotal studies. A
number of smaller phase II studies have also investigated
the weekly administration of both drugs, likewise report-
ing high response rates of 56 to 74% in patient popula-
tions with varying amounts of pretreatment [18-21].
Seidman et al. [20] administered a regimen similar to



















Logrank test: p = 0.0047
Figure 4 Time to progression by number of metastatic sites.pretreatment (30%), and achieved responses in about
70% of HER2-positive patients, with a median response
duration of 7 months. The smaller studies by Fountzilas
et al. [18] in 34 patients with no cytotoxic pretreatment
for advanced disease, and Gori et al. [21] in 25 patients,
most of whom had been heavily pretreated, showed simi-
lar efficacy with remission rates of 62% and 56%, and
median PFS of 9 and 8.6 months. Thus all these trials,
including our own with over 100 patients, are highly
consistent in reporting a level of efficacy that may be
slightly superior to that seen with the 3-weekly taxane30 35 40 45 50 55 60
onths
1 site: n = 47, 32 events, median = 10.8 months
> 1 sites: n = 59, 53 events, median = 8.1 months
Table 2 Adverse event frequency and severity (maximum
National Cancer Institute Common Toxicity Criteria [NCI
CTC] grade per category)
Adverse event/
organ system
Patients per NCI CTC grade [n (%)]
grade 1 grade 2 grade 3 grade 4
Hematological
White blood cells 33 (31) 22 (20) 9 (8) 6 (6)
Granulocytes 27 (26) 16 (15) 5 (5) 3 (3)
Platelets 16 (15) 2 (2) 3 (3) 1 (1)
Hemoglobin 43 (40) 40 (37) 3 (3) 3 (3)
Fever 20 (19) 8 (7)
Non-hematological
Hair loss 23 (21) 79 (73)
Nausea 53 (49) 15 (14)
Vomiting 32 (30) 10 (9)
Diarrhea 21 (19) 8 (7) 1 (1)
Constipation 18 (17) 1 (1)
Neurology/Motor 19 (18) 6 (6) 4 (4)
Neurology/Sensory 28 (26) 16 (15) 5 (5)
Arthralgia 27 (25) 9 (8) 2 (2)
Myalgia 20 (19) 8 (7) 3 (3)
Lung function 11 (10) 8 (7) 2 (2) 3 (3)
Pain 21 (19) 28 (26) 8 (7)
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vs weekly paclitaxel comes from the CALGB 9840 study,
which was also amended to incorporate trastuzumab for
all HER2-positive patients and on a randomized basis for
HER2-negative patients [22]. The dose-dense schedule
showed significantly superior response and time to pro-
gression, plus a distinctly favorable trend in overall sur-
vival and, as expected, no major antibody benefit in
HER2-negative patients.
Two phase II studies adding carboplatin to paclitaxel
and trastuzumab suggested even greater efficacy with re-
sponse rates >80% and median PFS markedly exceeding
1 year [23,24]. However, these results were achieved in
first-line patients only and must be weighed against sub-
stantial grade 3 to 4 myelosuppression. Weekly doce-
taxel + trastuzumab also appears a feasible combination
but has been investigated in very few patients [25].
As for safety, the randomized CALGB trial [22] sug-
gested that weekly, uninterrupted paclitaxel caused more
neuropathy and less hematotoxicity than the conven-
tional schedule, reflecting the clinical challenge of balan-
cing toxicity and efficacy in the optimization of palliative
treatment. However, in contrast to the other phase II/III
studies of weekly trastuzumab/paclitaxel [18,20-22] which
maintained the cytotoxic component until progression or
toxicity in most patients, we preferred to introduce a two
weeks break and, more importantly, to limit the duration of
chemotherapy so that it eventually lasted for less than onethird the median total duration of trastuzumab treatment.
As a consequence, we had to terminate treatment because
of toxicity in only 6% of patients, while the total median
duration of trastuzumab treatment (42 weeks) was dis-
tinctly longer than in the other phase II trials that reported
median therapy periods of less than half a year. This was
consistent with the low rate of severe sensory neuropathy
(5%), contrasting with the approximate 25% reported by
Seidman et al. [20,22]. Despite the anthracycline pretreat-
ment in all our patients, cardiotoxicity was rare, with clin-
ical symptoms reported in two cases only. This compares
favorably with the 11% grade 3–4 myocardial dysfunction
found in the pivotal study with 3-weekly paclitaxel [6]. The
other phase II trials of weekly paclitaxel reported rates of
2–8% but prior anthracycline was not a mandatory selec-
tion criterion in the two larger studies [18,20].
We consider our schedule combining two 6-week
courses of paclitaxel with concurrent and continued tras-
tuzumab to be a highly effective option feasible in the
vast majority of patients despite anthracycline pretreat-
ment. The finding in a recent meta-analysis that continu-
ation of first-line chemotherapy until disease progression
has at best a marginal effect on overall survival in most
patients [26] only bolsters the rationale for our de-
escalated approach.
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